Treatment of hepatitis C

被引：60

作者：

Heathcote, J

Main, J

机构：

[1] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Fac Med, London W2 1NY, England

[2] Univ Toronto, Toronto, ON, Canada

来源：

JOURNAL OF VIRAL HEPATITIS | 2005年 / 12卷 / 03期

关键词：

hepatitis C virus; pegylated interferon alpha; ribavirin;

D O I：

10.1111/j.1365-2893.2005.00600.x

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The combination of pegylated interferon alpha and ribavirin has improved treatment success rates in patients with hepatitis C with sustained response rates of just over 50% overall and more than 70% for those with genotypes 2 and 3. This article reviews the use of combination therapy, contraindications, factors influencing response and describes approaches to specific patient groups.

引用

收藏

页码：223 / 235

页数：13

相关论文

共 94 条

[1] Reversible cardiomyopathy secondary to α-interferon in an infant [J].

Angulo, MP ;

Navajas, A ;

Galdeano, JM ;

Astigarraga, I ;

Fernández-Teijeiro, A .

PEDIATRIC CARDIOLOGY, 1999, 20 (04) :293-294

[2] National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002 - June 10-12, 2002 [J].

不详 .

HEPATOLOGY, 2002, 36 (05) :S3-S20

[3] Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon alpha-2b and ribavirin in combination: an Italian pilot study [J].

Barbaro, G ;

Barbarini, G .

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2002, 14 (05) :477-483

[4] Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection [J].

Bica, I ;

McGovern, B ;

Dhar, R ;

Stone, D ;

McGowan, K ;

Scheib, R ;

Snydman, DR .

CLINICAL INFECTIOUS DISEASES, 2001, 32 (03) :492-497

[5] High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C [J].

Bressler, BL ;

Guindi, M ;

Tomlinson, G ;

Heathcote, J .

HEPATOLOGY, 2003, 38 (03) :639-644

[6] Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency [J].

Bruchfeld, A ;

Lindahl, K ;

Ståhle, L ;

Söderberg, M ;

Schvarcz, R .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (08) :1573-1580

[7]

Butt Adeel A, 2003, AIDS Read, V13, P344

[8] Interferon-α and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis [J].

Cacoub, P ;

Lidove, O ;

Maisonobe, T ;

Duhaut, P ;

Thibault, V ;

Ghillani, P ;

Myers, RP ;

Leger, JM ;

Servan, J ;

Piette, JC .

ARTHRITIS AND RHEUMATISM, 2002, 46 (12) :3317-3326

[9] Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy:: a meta-analysis of individual patient data [J].

Cammà, C ;

Bruno, S ;

Schepis, F ;

Lo Iacono, O ;

Andreone, P ;

Gramenzi, AG ;

Mangia, A ;

Andriulli, A ;

Puoti, M ;

Spadaro, A ;

Freni, M ;

Di Marco, V ;

Cino, L ;

Saracco, G ;

Chiesa, A ;

Crosignani ;

Caporaso, N ;

Morisco, F ;

Rumi, MG ;

Craxì, A .

GUT, 2002, 51 (06) :864-869

[10] Interferon and prevention of hepatocellular carcinoma in viral cirrhosis:: an evidence-based approach [J].

Cammà, C ;

Giunta, M ;

Andreone, P ;

Craxì, A .

JOURNAL OF HEPATOLOGY, 2001, 34 (04) :593-602

← 1 2 3 4 5 6 7 8 9 10 →